Search results
Showing 211 to 225 of 975 results for death
ID NG106/5 Question Risk tools for predicting non-sudden death in heart failure:- What is the most accurate prognostic risk tool in...
Evidence-based recommendations on nivolumab (Opdivo) as a possible treatment for completely resected oesophageal or gastro-oesophageal junction cancer in adults.
Maximal cytoreductive surgery for advanced ovarian cancer (HTG668)
Evidence-based recommendations on maximal cytoreductive surgery for advanced ovarian cancer. This involves removing all or almost all visible cancerous tissue. More tissue is removed than with standard surgery. The aim is to improve outcomes for people with advanced ovarian cancer.
View recommendations for HTG668Show all sections
Evidence-based recommendations on percutaneous fetal balloon valvuloplasty for pulmonary atresia with intact ventricular septum. This involves opening up the closed pulmonary valve of the babies heart while it is still in the womb using a balloon-like device.
View recommendations for HTG114Show all sections
Sections for HTG114
Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for HER2-low metastatic or unresectable breast cancer after chemotherapy in adults.
Mechanical clot retrieval for treating acute ischaemic stroke (HTG403)
Evidence-based recommendations on mechanical clot retrieval for treating acute ischaemic stroke in adults. This involves using a device to remove the blood clot from the brain to restore normal blood flow.
Evidence-based recommendations on icosapent ethyl (Vazkepa) with statin therapy for reducing the risk of cardiovascular events in adults with raised triglycerides.
Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (TA1018)
Evidence-based recommendations on fedratinib (Inrebic) for treating disease-related splenomegaly or symptoms of primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis in adults.
This guideline covers managing COVID-19 in babies, children, young people and adults in community and hospital settings. It includes recommendations on communication, assessment, therapeutics for COVID-19, non-invasive respiratory support, preventing and managing acute complications, and identifying and managing co-infections.
Evidence-based recommendations on stent insertion for bleeding oesophageal varices. This involves temporarily inserting a tube-shaped mesh covered in plastic (called a stent) into the oesophagus.
View recommendations for HTG261Show all sections
Sections for HTG261
Evidence-based recommendations on voretigene neparvovec (Luxturna) for RPE65-mediated inherited retinal dystrophies in people with vision loss caused by inherited retinal dystrophy from confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells.
Evidence-based recommendations on avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy in adults.
Fostamatinib for treating refractory chronic immune thrombocytopenia (TA835)
Evidence-based recommendations on fostamatinib (Tavlesse) for chronic refractory chronic immune thrombocytopenia in adults.
Evidence-based recommendations on the Pipeline Flex embolisation device with Shield Technology for the treatment of complex intracranial aneurysms.
Evidence-based recommendations on velmanase alfa (Lamzede) for treating alpha-mannosidosis in people under 18 years and in people who turn 18 while on treatment.